No better than less expensive drugsBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2914 (Published 24 April 2012) Cite this as: BMJ 2012;344:e2914
- Thomas L Perry, clinical assistant professor 1,
- Stephen S Lippman, endocrinologist2,
- Mark McConnell, internist2,
- Aaron M Tejani, research associate1
- 1Therapeutics Initiative, University of British Columbia, BC, Vancouver, Canada, V6T 1Z3
- 2Veterans Administration, Sacramento, CA, USA
The meta-analysis of short term studies using dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes indicates that they lower glycated haemoglobin (HbA1C) without causing weight gain or increasing mortality or serious adverse events. 1 In return, they increase drug costs.
However, drug treatment for type 2 diabetes aims to prevent or …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial